Additionally, PYY influences gut microbiota composition; emerging evidence links these microbiome shifts to slower MASLD progression, suggesting that PYY’s benefits extend beyond appetite suppression to include direct metabolic and microbial mechanisms (Figure 4). Here, PYY is linked to metabolic dysfunction-associated steatotic liver disease.